guest ::
| Home > Publications database > TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. > print |
| Home > Publications database > TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. > print |
| 001 | 168126 | ||
| 005 | 20240229133558.0 | ||
| 024 | 7 | _ | |a 10.1007/s00401-021-02300-8 |2 doi |
| 024 | 7 | _ | |a pmid:33755803 |2 pmid |
| 024 | 7 | _ | |a 0001-6322 |2 ISSN |
| 024 | 7 | _ | |a 1432-0533 |2 ISSN |
| 024 | 7 | _ | |a altmetric:102543433 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-00694 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Thomas, Christian |0 0000-0002-6642-7774 |b 0 |
| 245 | _ | _ | |a TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. |
| 260 | _ | _ | |a Heidelberg |c 2021 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1625054469_1990 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 141(6):959-970 |
| 520 | _ | _ | |a Subependymomas are benign tumors characteristically encountered in the posterior fossa of adults that show distinct epigenetic profiles assigned to the molecular group 'subependymoma, posterior fossa' (PFSE) of the recently established DNA methylation-based classification of central nervous system tumors. In contrast, most posterior fossa ependymomas exhibit a more aggressive biological behavior and are allocated to the molecular subgroups PFA or PFB. A subset of ependymomas shows epigenetic similarities with subependymomas, but the precise biology of these tumors and their potential relationships remain unknown. We therefore set out to characterize epigenetic traits, mutational profiles, and clinical outcomes of 50 posterior fossa ependymal tumors of the PFSE group. On histo-morphology, these tumors comprised 12 ependymomas, 14 subependymomas and 24 tumors with mixed ependymoma-subependymoma morphology. Mixed ependymoma-subependymoma tumors varied in their extent of ependymoma differentiation (2-95%) but consistently exhibited global epigenetic profiles of the PFSE group. Selective methylome analysis of microdissected tumor components revealed CpG signatures in mixed tumors that coalesce with their pure counterparts. Loss of chr6 (20/50 cases), as well as TERT mutations (21/50 cases), were frequent events enriched in tumors with pure ependymoma morphology (p < 0.001) and confined to areas with ependymoma differentiation in mixed tumors. Clinically, pure ependymoma phenotype, chr6 loss, and TERT mutations were associated with shorter progression-free survival (each p < 0.001). In conclusion, our results suggest that subependymomas may acquire genetic and epigenetic changes throughout tumor evolution giving rise to subclones with ependymoma morphology (resulting in mixed tumors) that eventually overpopulate the subependymoma component (pure PFSE ependymomas). |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Chromosome 6 |2 Other |
| 650 | _ | 7 | |a DNA methylation |2 Other |
| 650 | _ | 7 | |a Mixed ependymoma–subependymoma |2 Other |
| 650 | _ | 7 | |a Subependymoma |2 Other |
| 650 | _ | 7 | |a TERT |2 Other |
| 700 | 1 | _ | |a Thierfelder, Felix |0 P:(DE-He78)560b340ec11109efc8f88c383f51ba8e |b 1 |u dkfz |
| 700 | 1 | _ | |a Träger, Malte |b 2 |
| 700 | 1 | _ | |a Soschinski, Patrick |b 3 |
| 700 | 1 | _ | |a Müther, Michael |b 4 |
| 700 | 1 | _ | |a Edelmann, Dominic |0 P:(DE-He78)92820b4867c955a04f642707ecf35b40 |b 5 |u dkfz |
| 700 | 1 | _ | |a Förster, Alexandra |b 6 |
| 700 | 1 | _ | |a Geiler, Carola |b 7 |
| 700 | 1 | _ | |a Kim, Hee-Yeong |0 P:(DE-He78)96b5c6d770f3aa58db900d1434f5a3f5 |b 8 |u dkfz |
| 700 | 1 | _ | |a Filipski, Katharina |0 P:(DE-He78)832f5277c0186f22e7704f1930239636 |b 9 |u dkfz |
| 700 | 1 | _ | |a Harter, Patrick |0 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff |b 10 |
| 700 | 1 | _ | |a Schittenhelm, Jens |b 11 |
| 700 | 1 | _ | |a Eckert, Franziska |b 12 |
| 700 | 1 | _ | |a Ntoulias, Georgios |b 13 |
| 700 | 1 | _ | |a May, Sven-Axel |b 14 |
| 700 | 1 | _ | |a Stummer, Walter |b 15 |
| 700 | 1 | _ | |a Onken, Julia |b 16 |
| 700 | 1 | _ | |a Vajkoczy, Peter |b 17 |
| 700 | 1 | _ | |a Schüller, Ulrich |b 18 |
| 700 | 1 | _ | |a Heppner, Frank L |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Capper, David |0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c |b 20 |u dkfz |
| 700 | 1 | _ | |a Koch, Arend |0 P:(DE-HGF)0 |b 21 |
| 700 | 1 | _ | |a Kaul, David |b 22 |
| 700 | 1 | _ | |a Paulus, Werner |b 23 |
| 700 | 1 | _ | |a Hasselblatt, Martin |b 24 |
| 700 | 1 | _ | |a Schweizer, Leonille |0 P:(DE-He78)db2e8cf0dd8fa826896839ffee4b1411 |b 25 |u dkfz |
| 773 | _ | _ | |a 10.1007/s00401-021-02300-8 |0 PERI:(DE-600)1458410-4 |n 6 |p 959-970 |t Acta neuropathologica |v 141 |y 2021 |x 1432-0533 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:168126 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)560b340ec11109efc8f88c383f51ba8e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)92820b4867c955a04f642707ecf35b40 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)96b5c6d770f3aa58db900d1434f5a3f5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)832f5277c0186f22e7704f1930239636 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-He78)db2e8cf0dd8fa826896839ffee4b1411 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-29 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-01-29 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-29 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACTA NEUROPATHOL : 2019 |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-29 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-29 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ACTA NEUROPATHOL : 2019 |d 2021-01-29 |
| 920 | 1 | _ | |0 I:(DE-He78)BE01-20160331 |k BE01 |l DKTK BE zentral |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)FM01-20160331 |k FM01 |l DKTK FM zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)BE01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)FM01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|